A Clinical Analysis Of AIDS-related Non-Hodgkin Lymphoma In9Patients

Objective: AIDS-related non-Hodgkin lymphoma (ARL) is one of the mostcommon AIDS-related malignancies. With the widely use of highly active antiretroviral therapy (HAART)， the patient’s immune function and thetolerance to chemotherapy with ARL has been improved, and the prognosis ofmany patients has been significantly improved.By analyzing the clinicalcharacteristics of AIDS-related non-Hodgkin lymphoma(ARL), we raiseunderstanding the diagnosis and treatment of ARL．Methods: The clinical data of9ARL patients admitted to Jilin tumorHospital and Japanese Friendship Hospital of Jilin University from March2011to AUG2012were retrospectively analyzed．Result: Nine male ARL patients aged28to65years old were included in thisretrospective study.Among them,six patients were found to be HIV—positivein1year before the diagnosis of lymphoma and during antiretroviral therapy(HAART) in the diagnosis of NHL,one patient was found to be HIV-positive in 2year and interruptted HAART treatment due to the side effects can not betolerated, continued HAART treatment after the diagnosis of ARL,2patientswas founded HIV infection after the lymphoma diagnosis and treatment;CD3+T cell count was(69—294)×106／L at presentation．Two patients firstlypresented with Oral tumor，two with sore throat and throat ulcer，one withgingival tumor，one with the palate tumor，two with fever and edema in rightthigh,one with the lymph-nodes,one with neck mass,the other with abdominaland pelvic placeholder．Through pathological analysis，three patients had B cell—originated lymphoma,four patients had diffuse large B-cell lymphoma,onepatients with T-cell lymphoma, the other patients with Burkitt lymphoma. Eightcases were treated with systemic chemotherapy and targeted therapy,radiotherapy combined therapy, the other patient received radiotherapyonly.Seven patients were treated with chemotherapy and HAART treatment,2patients were traaeted with chemotherapy after the start of the HAARTtreatment in3months. Three patients abtained complete remission (includingone case relapsed after the follow-up six months), two patients abtained partial remission, one patient does not get better, until switching the thechemotherapy, one patient died and another dided the progress of the diseaseafter the efficacy of once of PR,one case of disease progression.Bone marrowsuppression were the main adverse effects of therapy．Conclusion: ARL，appropriate chemotherapy，together with HAART andrituximab，may improve the prognosis greatly．...